🏛️ Verified NIH Record • Updated 2026-05-29
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06625320)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Revolution Medicines, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (6 items).
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
- History of or known central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study treatment
- Major surgery within 4 weeks prior to randomization.
- Patient is unable or unwilling to comply with protocol-required study visits or procedures
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (60 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Cancer Center - Phoenix — Phoenix, Arizona
- City of Hope-Duarte — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA — Los Angeles, California
- UC San Diego Health Moores Cancer Center — San Diego, California
- Mission Hall UCSF — San Francisco, California
- Rocky Mountain Cancer — Aurora, Colorado
- Mayo Clinic Cancer Center - Florida — Jacksonville, Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
- Cancer Care Centers of Brevard Inc — Palm Bay, Florida
- Moffitt Cancer Center — Tampa, Florida
- The Queen's Medical Center — Honolulu, Hawaii
- The University of Chicago Medical Center — Chicago, Illinois
- Johns Hopkins — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Mayo Clinic Cancer Center - Rochester — Rochester, Minnesota
- Washington University — St Louis, Missouri
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Lagone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Columbia University Medical Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.